Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $6.6 million.

  • Cartesian Therapeutics' Share-based Compensation rose 52.80% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 45.70%. This contributed to the annual value of $6.6 million for FY2024, which is 70.78% down from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Share-based Compensation is $6.6 million, which was down 70.78% from $22.5 million recorded in FY2023.
  • Cartesian Therapeutics' Share-based Compensation's 5-year high stood at $22.5 million during FY2023, with a 5-year trough of $5.4 million in FY2020.
  • For the 3-year period, Cartesian Therapeutics' Share-based Compensation averaged around $13.4 million, with its median value being $11.2 million (2022).
  • As far as peak fluctuations go, Cartesian Therapeutics' Share-based Compensation soared by 101.21% in 2023, and later crashed by 70.78% in 2024.
  • Cartesian Therapeutics' Share-based Compensation (Yearly) stood at $5.4 million in 2020, then spiked by 42.38% to $7.7 million in 2021, then surged by 45.00% to $11.2 million in 2022, then spiked by 101.21% to $22.5 million in 2023, then slumped by 70.78% to $6.6 million in 2024.